A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)

Oronsky, Bryan; Abrouk, Nacer; Caroen, Scott; Lybeck, Michelle; Guo, Xiaoning; Wang, Xiaohui; Yu, Zhang; Reid, Tony

doi:10.7150/jca.75622

Cited by 23 publications

(16 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The selection of comparators in the model is an important issue to consider when performing a cost-effectiveness analysis. The combination of durvalumab or atezolizumab with chemotherapy as a first-line treatment option for ES-SCLC has been approved by the Food and Drug Administration but this was not assessed in our study ( Oronsky et al, 2022 ). From a Chinese perspective analysis, neither treatment option is cost-effective compared to chemotherapy ( Li et al, 2019 ; Liu and Kang, 2022 ; Tong et al, 2022 ).…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer

You

Chen²,

Wu³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: The findings of the CAPSTONE-1 trial showed that adebrelimab in combination with chemotherapy (etoposide-carboplatin) (ADCHM) is clinically beneficial as a first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), compared with placebo plus chemotherapy (PLCHM, etoposide-carboplatin). However, owing to the higher cost of adebrelimab, it is unclear whether ADCHM is cost-effective compared with PLCHM. This study aimed to evaluate the cost-effectiveness of ADCHM as a first-line treatment for patients with ES-SCLC from the perspective of the Chinese healthcare system.Methods: A Markov model with three health states was developed to assess the cost-effectiveness of ADCHM as a first-line treatment option with ES-SCLC. Clinical data were obtained from the CAPSTONE-1 trial. Costs of the drug were calculated at national tender prices, and other costs and utility values were obtained from published literature. The outcomes included life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). One-way sensitivity analysis and probabilistic sensitivity analysis were used to validate the robustness of the model.Results: The ADCHM group achieved 1.21 QALYs (2.47 LYs) for $25,312, whereas the PLCHM group achieved 0.81 QALYs (1.59 LYs) for $14,846. The ICER for ADCHM versus PLCHM was $25914 per QALY gained. The variables with the greatest impact on the model results were the utility value of progressive disease, the utility value of progression-free survival, and the price of adebrelimab (100 mg). At a willingness-to-pay threshold of $37,653/QALY, ADCHM had an 89.1% probability of being cost-effective compared with PLCHM.Conclusion: ADCHM may be a cost-effective first-line treatment strategy for ES-SCLC from the perspective of the Chinese healthcare system.

show abstract

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer

You

Chen²,

Wu³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Due to the quick multiplication time in small cell lung cancer (SCLC), lung cancer has a poor prognosis (de Groot et al, 2018;Barta et al, 2019;Schabath and Cote, 2019;Thandra et al, 2021). Chemotherapy is the primary therapeutic option for advanced SCLCs but has significant side effects, including an increased risk of cancer recurrence (Yang et al, 2019;Oronsky et al, 2022). Contrarily, biological therapy is regarded as a secure and effective therapeutic approach.…”

Section: Hepatocellular Carcinomamentioning

confidence: 99%

Trichinella spiralis as a Potential Antitumor Agent: An Update

Sadr¹,

Yousefsani²,

Simab³

et al. 2023

WVJ

View full text Add to dashboard Cite

Due to the limited success of therapeutic strategies in treating tumors, a new practical potent approach is needed. This review aimed to investigate previous literature related to tumors and Trichinella spiralis (T. spiralis). In recent years, there has been growing interest in utilizing biological, viral, bacterial, yeast, and parasitic agents to cure cancers. According to several studies, some parasites could interferee with the tumors’ growth. There has been much discussion about some parasites’ applications to cure tumors in animals and humans. In studies, T. spiralis was found to have antitumor properties. The active proteins in T. spiralis, such as Caveolin-1, Heat shock proteins, and Ribosomal proteins, are thought to inhibit the growth of cancers, such as melanoma, myeloma, sarcoma, leukemia, stomach cancer, colon cancer, breast cancer, and lung cancer. In addition, these proteins are thought to induce apoptosis in specific neoplastic cells. Accordingly, antigens derived from parasites may be helpful in cancer immunotherapy. However, there are still many unanswered questions regarding Trichinella spiralis’ potential use as a biotherapy agent against cancer. Future studies should focus on the purification of parasite antigens and their use for wider-scale trials in animal models.

show abstract

“…122 In an ongoing Phase 3 trial, RRx-001 is being tested in combination with carboplatin/cisplatin and etoposide for the treatment of SCLC. 123 Pyroptosis-related genes have potential therapeutic applications, but they are also beneficial in the prediction of lung cancer prognosis. GSDME, caspase 3, and caspase 8 are more abundantly expressed in tumor tissue.…”

Section: Nlrp3mentioning

confidence: 99%

Pyroptosis and inflammasomes in cancer and inflammation

Wang,

Hua,

Bao

et al. 2023

MedComm

View full text Add to dashboard Cite

Nonprogrammed cell death (NPCD) and programmed cell death (PCD) are two types of cell death. Cell death is significantly linked to tumor development, medication resistance, cancer recurrence, and metastatic dissemination. Therefore, a comprehensive understanding of cell death is essential for the treatment of cancer. Pyroptosis is a kind of PCD distinct from autophagy and apoptosis in terms of the structure and function of cells. The defining features of pyroptosis include the release of an inflammatory cascade reaction and the expulsion of lysosomes, inflammatory mediators, and other cellular substances from within the cell. Additionally, it displays variations in osmotic pressure both within and outside the cell. Pyroptosis, as evidenced by a growing body of research, is critical for controlling the development of inflammatory diseases and cancer. In this paper, we reviewed the current level of knowledge on the mechanism of pyroptosis and inflammasomes and their connection to cancer and inflammatory diseases. This article presents a theoretical framework for investigating the potential of therapeutic targets in cancer and inflammatory diseases, overcoming medication resistance, establishing nanomedicines associated with pyroptosis, and developing risk prediction models in refractory cancer. Given the link between pyroptosis and the emergence of cancer and inflammatory diseases, pyroptosis‐targeted treatments may be a cutting‐edge treatment strategy.

show abstract

A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)

Cited by 23 publications

References 58 publications

Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer

Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer

Trichinella spiralis as a Potential Antitumor Agent: An Update

Pyroptosis and inflammasomes in cancer and inflammation

Contact Info

Product

Resources

About